What is it about?

Limited data are available on risk of venous thromboembolism (VTE) in disease-modifying antirheumatic drug (DMARD) users. This study aimed to assess incidence rates (IR) of VTE in patients with rheumatoid arthritis (RA) on different DMARDs and DMARDs switchers. A retrospective cohort study of adults with RA (PE/DVT) on a DMARD between 2007-2017 in a US claims database were conducted to assess IR of inpatient VTE among those who were conventional synthetic DMARDs (csDMARDs) users, first biologic/targeted synthetic DMARD (b/tsDMARD) users, and b/tsDMARD switchers (from a b/tsDMARD to another b/tsDMARD). Findings indicated that b/tsDMARD switchers were associated with increased risk of VTE after controlling for age, sex and race, compared with first b/tsDMARD users and csDMARD users. Further adjusting for some risk factors for VTE weakened this association, suggesting that switching b/tsDMARDs may be a proxy for higher disease severity or poorly controlled RA. Switching b/tsDMARDs could be an important confounder to consider in obtaining unbiased estimates of VTE risk in observational RA safety studies.

Featured Image

Read the Original

This page is a summary of: Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting, RMD Open, September 2019, BMJ,
DOI: 10.1136/rmdopen-2019-001013.
You can read the full text:

Read

Contributors

Be the first to contribute to this page